Translate this page to:
In JoVE (1)
Other Publications (2)
This translation into Hebrew was automatically generated.
English Version | Other Languages
Articles by Matthew G. Landry in JoVE
חלבון נמוך מולקולרית משקל העשרה על סרטים סיליקה mesoporous דק גילוי סמן ביולוגי
Jia Fan1,2, James W. Gallagher1, Hung-Jen Wu1, Matthew G. Landry1, Jason Sakamoto1, Mauro Ferrari1, Ye Hu1
1Department of Nanomedicine, The Methodist Hospital Research Institute, 2CAS Key Laboratory for Biological Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology
פיתחנו טכנולוגיה המבוססת על הסרט סיליקה mesoporous דק להתאוששות סלקטיבית של חלבונים נמוך משקל מולקולרי ופפטידים מ בסרום אדם. פיסיקלי כימי את המאפיינים של שבבי mesoporous שלנו היו מכוון היטב כדי לספק שליטה משמעותית להעשרת פפטיד ולכן פרופיל proteome סרום למטרות אבחון.
Other articles by Matthew G. Landry on PubMed
Cancer Science. Jul, 2011 | Pubmed ID: 21447010
Cancer is a leading cause of morbidity and mortality worldwide, with recent advancements resulting in modest impacts on patient survival. Nanomedicine represents an innovative field with immense potential for improving cancer treatment, having ushered in several established drug delivery platforms. Nanoconstructs such as liposomes are widely used in clinics, while polymer micelles are in advanced phases of clinical trials in several countries. Currently, the field of nanomedicine is generating a new wave of nanoscale drug delivery strategies, embracing trends that involve the functionalization of these constructs with moieties that enhance site-specific delivery and tailored release. Herein, we discuss several advancements in established nanoparticle technologies such as liposomes, polymer micelles, and dendrimers regarding tumor targeting and controlled release strategies, which are being incorporated into their design with the hope of generating a more robust and efficacious nanotherapeutic modality. We also highlight a novel strategy known as multistage drug delivery; a rationally designed nanocarrier aimed at overcoming numerous biological barriers involved in drug delivery through the decoupling of various tasks that comprise the journey from the moment of systemic administration to arrival at the tumor site.
Molecular Oncology. Dec, 2011 | Pubmed ID: 22071376
Chemotherapy represents a mainstay and powerful adjuvant therapy in the treatment of cancer. The field has evolved from drugs possessing all-encompassing cell-killing effects to those with highly targeted, specific mechanisms of action; a direct byproduct of enhanced understanding of tumorigenic processes. However, advances regarding development of agents that target key molecules and dysregulated pathways have had only modest impacts on patient survival. Several biological barriers preclude adequate delivery of drugs to tumors, and remain a formidable challenge to overcome in chemotherapy. Currently, the field of nanomedicine is enabling the delivery of chemotherapeutics, including repositioned drugs and siRNAs, by giving rise to carriers that provide for protection from degradation, prolonged circulation times, and increased tumor accumulation, all the while resulting in reduced patient morbidity. This review aims to highlight several innovative, nanoparticle-based platforms with the potential of providing clinical translation of several novel chemotherapeutic agents. We will also summarize work regarding the development of a multistage drug delivery strategy, a robust carrier platform designed to overcome several biological barriers while en route to tumors.